A new technology company is poised to address one of the most persistent challenges in drug development - patient medication adherence in clinical trials. Validose, a 10XBeta Venture Studio portfolio company, has secured $2 million in pre-seed funding to advance its precision medication delivery platform.
The funding round, led by Peter Bauer's Family Office as part of its Technology for Humanity strategy, along with 10XBeta and Interstate Fusion Ventures, will primarily support the development of the company's first product - a smart-dose eyedropper scheduled for launch in Q2 2025.
Revolutionary Approach to Clinical Trial Adherence
Validose's platform represents a significant departure from traditional adherence monitoring methods, which typically rely on patient self-reporting through written journals or tracking apps. The company's solution integrates sophisticated technology with standard drug packaging, providing real-time adherence data while delivering personalized behavioral support to improve patient compliance.
"Validose is addressing a critical challenge in drug development: clinical trial failures due to patient non-adherence," explains Paul McGrath, CEO of Validose. "Non-adherence significantly raises costs and delays healthcare innovation. While existing solutions offer delayed or passive adherence monitoring, Validose has introduced a proactive, real-time adherence platform that reshapes patient behavior, enhances trial oversight, and accelerates decision-making."
Advanced Technology Platform
The cornerstone of Validose's innovation is its Dose Exoskeleton - a multi-sensor, adaptable attachment that captures adherence metrics across various medication forms. This versatile technology can be applied to multiple drug delivery formats, including nasal sprays, ophthalmic drops, and other therapeutic applications, ensuring precise tracking and scalability.
The platform's comprehensive solution includes:
- A Patient Portal featuring personalized dose reminders, real-time messaging, and behavioral coaching
- A Clinician Dashboard providing immediate access to adherence data and enabling timely interventions
- Behavioral prompts and engagement tools to maintain patient compliance throughout the trial
Addressing a Critical Industry Challenge
Non-adherence contributes to the failure of approximately 30% of drug clinical trials, representing a significant obstacle in the drug development process. This issue is particularly critical in trials where non-adherence can lead to serious adverse health effects and where patient recruitment is already challenging.
"At 10XBeta, we are committed to bringing together founders, capital, investors, and talent to launch MedTech solutions that tackle the most significant challenges facing the healthcare industry," stated a 10XBeta representative. "We are proud to support Validose in developing cutting-edge technology with the potential to drive significant improvements in clinical trials."
Smart Technology Integration
The platform's intelligent design allows it to integrate seamlessly with existing drug packaging while providing advanced features that benefit both patients and trial coordinators. The system's ability to capture objective, precise, and secure real-time adherence data represents a significant advancement over current market standards, where adherence tracking is often inconsistent or overlooked entirely.
As Validose prepares for its initial product launch, the company's innovative approach to medication adherence monitoring and support has the potential to significantly improve clinical trial outcomes and accelerate the drug development process.
